Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» R&D
R&D
Biogen splits R&D executive role, promoting interim head Singhal
BioPharma Dive
Thu, 01/5/23 - 04:47 pm
Biogen
R&D
Merck KGaA hands over IL-12-targeting cancer med to PDS Biotech in $121M deal
Fierce Biotech
Tue, 01/3/23 - 10:26 pm
Merck KGaA
R&D
PDS Biotechnology
How a US Recession Could Affect Biopharma
BioSpace
Thu, 12/22/22 - 10:54 am
economy
biotech
recession
clinical trials
R&D
pandemic
Catalent to build a new $40M analytical services facility in North Carolina's Research Triangle
Endpoints
Wed, 12/14/22 - 07:25 pm
Catalent
North Carolina
RTP
analytical services
R&D
AbbVie, Ipsen exit R&D deals to cap off lousy year for Exicure
Fierce Biotech
Wed, 12/14/22 - 10:44 am
Exicure
AbbVie
Ipsen
R&D
Teva-partnered MedinCell bags $42M loan for long-acting injectable R&D
Fierce Pharma
Wed, 11/30/22 - 10:35 am
MedinCell
Teva Pharmaceutical
injectables
R&D
Merck to Leverage BigHat's AI Platform in 3 Drug Discovery Programs
BioSpace
Tue, 11/29/22 - 08:25 pm
Merck
BigHat Biosciences
R&D
artificial intelligence
Envisagenics Announces Research Collaboration with Bristol Myers Squibb
BioSpace
Tue, 11/29/22 - 10:40 am
Envisagenics
artificial intelligence
Bristol Myers Squibb
R&D
Black Friday for Spectrum as FDA lung cancer rejection prompts 75% cut to R&D workforce
Fierce Biotech
Mon, 11/28/22 - 10:40 am
Spectrum Pharmaceuticals
layoffs
R&D
FDA
Pozenveo
Novo Nordisk invests $74M to boost API manufacturing for clinical trials
Fierce Biotech
Tue, 11/22/22 - 10:52 am
Novo Nordisk
clinical trials
APIs
API manufacturing
R&D
Merck KGaA outlines plan to rev up drug R&D
BioPharma Dive
Mon, 11/21/22 - 06:36 pm
Merck KGaA
drug development
R&D
Nabriva halts R&D, lays off 40% of staff in commercial-focused pivot for survival
Fierce Biotech
Fri, 11/11/22 - 10:46 am
Nabriva Therapeutics
R&D
layoffs
Sivextro
Harbour BioMed, Moderna partner on immunotherapies development
Pharmaceutical Business Review
Fri, 11/11/22 - 10:34 am
Harbour BioMed
Nana Biosciences
Moderna Therapeutics
immunotherapies
R&D
IQVIA and Clalit Health to launch prime site in Israel
Clinical Trials Arena
Fri, 11/11/22 - 10:30 am
IQVIA
Clalit Health
Israel
R&D
clinical trials
Sanofi Reaffirms Commitment to AI Drug Discovery with $1.2B Insilico Pact
BioSpace
Tue, 11/8/22 - 10:30 pm
Sanofi
artificial intelligence
Insilico
drug discovery
R&D
Sanofi Secures Access to Salipro's Protein Stabilization Tech in R&D Deal
BioSpace
Tue, 11/8/22 - 10:25 pm
Sanofi
Salipro
R&D
Pfizer discards eczema, NASH and breast cancer programs in early-phase clean-out
Fierce Biotech
Tue, 11/1/22 - 12:09 pm
Pfizer
R&D
NASH
breast cancer
eczema
Covid-19 spurred a historic vaccine R&D effort. What does it mean for future pandemics?
Endpoints
Tue, 11/1/22 - 11:06 am
COVID-19
vaccines
R&D
Corbevax
pandemic
EpiVax partners with Intravacc, CEPI for betacoronavirus vaccine development
Pharmaceutical Business Review
Tue, 11/1/22 - 11:01 am
EpiVax
Invravacc
CEPI
vaccines
R&D
betacoronaviruses
COVID-19
Autoimmune drug biotech HI-Bio unveils $120M to root out cellular drivers of disease
MedCity News
Tue, 11/1/22 - 10:55 am
Human Immunology Bioscience
autoimmune disease
R&D
MorphoSys
kidney disease
Pages
« first
‹ previous
…
3
4
5
6
7
8
9
10
11
…
next ›
last »